Fig. 1 · Structure

Documents & Downloads

RIPA-56

Cat. No. A12473 CAS 1956370-21-0

RIP1 inhibitor

RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) with an IC50 of 13 nM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

RIPA-56 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of RIPA-56 from 3 published references. In vitro models include POMGnT1-knockout (KO) human retinal pigment epithelial (hRPE) cells; organotypic hippocampal slice cultures from male rats.

RIPA-56 In Vitro Studies

In POMGnT1-knockout human retinal pigment epithelial cells, ATP concentrations after 40 µM RIPA-56 treatment were 103.7 ± 6.1% of wild-type levels. In organotypic hippocampal slice cultures from male rats, the lower NO release observed with TNFα + IFNγ + I19 compared with TNFα + IFNγ was not observed with RIPA-56. In POMGnT1-/- RPE cells, 40 µM RIPA-56 for 24 h significantly reduced phosphorylation of RIP1, RIP3, and MLKL. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

ATP concentrations in POMGnT1-knockout retinal pigment epithelial cells

Cell-based study · POMGnT1-knockout (KO) human retinal pigment epithelial (hRPE) cells [1]

POMGnT1-knockout human retinal pigment epithelial cells were treated with 40 µM RIPA-56. ATP concentrations after treatment were 103.7 ± 6.1% of wild-type levels.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ATP concentrations were quantified and expressed as a percentage of wild-type levelsATP concentrations 103.7 ± 6.1%[1]

Literature-Reported Treatment Conditions

Treatment concentration
40 µM
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route, schedule.
Methods and source locations

Compound reported in the paper: RIPA-56

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > AAV8-hPOMGnT1 and RIPA-56 rescue ATP production in POMGnT1-knockout hRPE cells (S156, S157, S158, S159); Materials and Methods > Cell culture (S233)

ATP concentrations were quantified and expressed as a percentage of wild-type levels: ATP concentrations were quantified and expressed as a percentage of wild-type levels; comparator: KO controls — Results > AAV8-hPOMGnT1 and RIPA-56 rescue ATP production in POMGnT1-knockout hRPE cells (S156, S157, S159)

Nitrite content in organotypic hippocampal slice cultures from male rats

Cell-based study · organotypic hippocampal slice cultures from male rats [2]

Model: organotypic hippocampal slice cultures from male rats. Treatment: 100 µM. Result: RIPA-56 (R56, 100 µM when alone): NO release was lower in slice cultures exposed to TNFα + IFNγ + I19 compared with TNFα + IFNγ, an effect not observed for R56..

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Nitrite contentReported result RIPA-56 (R56, 100 µM when alone): NO release was lower in slice cultures exposed to TNFα + IFNγ + I19 compared with TNFα + IFNγ, an effect not observed for R56.[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 µM
Exposure duration
for 72 h with or without simultaneous exposure
Method
added to the medium
Co-treatment
Other interventions in this design: TNF-α 100 ng/mL; IFN-γ 100 ng/mL. Compound effect isolated by the comparison: TNFα + IFNγ.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: RIPA-56

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Exposures and microglial ablation (S15); Materials and methods > Biochemical assays (S30); Results (S168); Results > Inhibition of TNFR1 signaling protects neural gamma oscillations (S313, S317, S328)

Nitrite content: Nitrite content; comparator: TNFα + IFNγ — Results > Inhibition of TNFR1 signaling protects neural gamma oscillations (S313, S317, S328)

Phosphorylation changes in POMGnT1-knockout retinal pigment epithelial cells

Cell-based study · POMGnT1-/- RPE cells [1]

POMGnT1-/- RPE cells were treated with 40 µM RIPA-56 for 24 h. Treatment significantly reduced phosphorylation of RIP1, RIP3, and MLKL.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
phosphorylation of RIP1, RIP3, and MLKLReported result Following treatment with 40 µM RIPA-56 for 24 h, RIPA-56 significantly reduced the phosphorylation of RIP1, RIP3, and MLKL.[1]

Literature-Reported Treatment Conditions

Treatment concentration
40 µM
Exposure duration
24 h
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: RIPA-56

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > RIPA-56 attenuates necroptosis-induced cell death and restores paracellular permeability in human retinal pigment epithelial (RPE) cells by targeting the RIP1 pathway (S110, S112, S114, S122); Materials and Methods > Cell culture (S233)

phosphorylation of RIP1, RIP3, and MLKL: phosphorylation of RIP1, RIP3, and MLKL; comparator: POMGnT1 knockout (POMGnT1-/-) — Results > RIPA-56 attenuates necroptosis-induced cell death and restores paracellular permeability in human retinal pigment epithelial (RPE) cells by targeting the RIP1 pathway (S114, S122)

RIPA-56 In Vivo Studies

In male mice with NMDA-induced retinal injury, intravitreal RIPA-56 at 60 µM or 80 µM increased relative RGC density compared with the NMDA group. At 100 µM, relative RGC density was 55.49 ± 4.19%, with no statistically significant difference from the NMDA group. [3]

Retinal ganglion cell density following NMDA-induced retinal injury

Animal study · C57 BL/6J male mice; NMDA-induced mice retinal injury model; n = 4 [3]

Male C57 BL/6J mice with NMDA-induced retinal injury received intravitreal RIPA-56 at 60 µM, 80 µM, or 100 µM. Relative RGC density increased to 61.76 ± 3.54% and 76.52 ± 4.41% at 60 µM and 80 µM, respectively, compared with 51.36 ± 4.00% in the NMDA group. At 100 µM, density was 55.49 ± 4.19%, with no statistically significant difference from the NMDA group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative RGCs densityRelative RGCs density 61.76 ± 3.54%, 76.52 ± 4.41%, 55.49 ± 4.19%[3]

Conditions shared by the study groups

Route
injected into the vitreous cavity
Treatment course
3 days later
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
RIPA-56 60 µM, 80 µM, 100 µMNMDA group (51.36 ± 4.00%)Treatment with 60 µM (61.76 ± 3.54%) or 80 µM (76.52 ± 4.41%) Ripa-56 resulted in increased RGC density compared to the NMDA group (51.36 ± 4.00%); 100 µM, the RGCs density decreased (55.49 ± 4.19%); the difference was not statistically significant when compared to the NMDA group[3]
RIPA-56 60 µM, 80 µM, 100 µM
Model: C57 BL/6J male mice; NMDA-induced mice retinal injury model; n = 4
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: RIPA-56

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animals (S13); Materials and methods > NMDA-induced retinopathy mouse model (S19, S22); Materials and methods > Immunofluorescence assay and RGCs counting (S40); Results > Ripa-56 protects mice from NMDA-induced retinal injury (S96, S97, S98, S99, S100, S101, S102, S103)

Relative RGCs density: Relative RGCs density; comparator: NMDA group (51.36 ± 4.00%) — Results > Ripa-56 protects mice from NMDA-induced retinal injury (S96, S97, S103)

RIPA-56 60 µM, 80 µM, 100 µM · Results > Ripa-56 protects mice from NMDA-induced retinal injury (S96, S97, S100, S101, S103)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1956370-21-0
Applications RIP1 inhibitor
Formula C13H19NO2
Molecular Weight 221.3
SMILES
CCC(C)(C)C(N(CC1=CC=CC=C1)O)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 38 mg/mL (171.71 mM)
Water Insoluble
Ethanol 38 mg/mL (171.71 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

RIPA-56 Research References

  1. [1] Chien JY, Woon PY, Tsai HY, et al. Glycosylation-driven necroptosis in retinal degeneration: dual rescue by AAV8 gene therapy and RIPK1 inhibition. Cell Death Discov (2026). PMID: 41957343 DOI: 10.1038/s41420-026-03098-8 Source material
  2. [2] Malorny N, Chausse B, Khodaie B, et al. TNF-α and IFN-γ impair neural oscillations and induce neurodegeneration by microglial nitric oxide, metabolic and oxidative stress. J Neuroinflammation (2026). PMID: 42104415 DOI: 10.1186/s12974-026-03835-x Source material
  3. [3] Feng L, Dai S, Zhang C, et al. Ripa-56 protects retinal ganglion cells in glutamate-induced retinal excitotoxic model of glaucoma. Sci Rep (2024). PMID: 38360971 DOI: 10.1038/s41598-024-54075-z Source material

Added to your cart

View Cart Checkout
Loading...